PE20210452A1 - Inhibidores de la arginasa - Google Patents
Inhibidores de la arginasaInfo
- Publication number
- PE20210452A1 PE20210452A1 PE2020001352A PE2020001352A PE20210452A1 PE 20210452 A1 PE20210452 A1 PE 20210452A1 PE 2020001352 A PE2020001352 A PE 2020001352A PE 2020001352 A PE2020001352 A PE 2020001352A PE 20210452 A1 PE20210452 A1 PE 20210452A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- arginase inhibitors
- arg2
- arg1
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000004452 Arginase Human genes 0.000 title 1
- 108700024123 Arginases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100021723 Arginase-1 Human genes 0.000 abstract 2
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 abstract 2
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 abstract 2
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 abstract 2
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se describen compuestos que son inhibidores de al menos uno de ARG1 y ARG2 y composiciones que contienen los compuestos y metodos para sintetizar los compuestos. En el presente documento tambien se describe el uso de tales compuestos y composiciones para el tratamiento de una diversidad de enfermedades, trastornos y afecciones, incluidos los trastornos relacionados con el cancer y con el sistema inmunitario que estan mediados, al menos en parte, por ARG1 y ARG2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638412P | 2018-03-05 | 2018-03-05 | |
| PCT/US2019/020507 WO2019173188A1 (en) | 2018-03-05 | 2019-03-04 | Arginase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210452A1 true PE20210452A1 (es) | 2021-03-08 |
Family
ID=67847429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001352A PE20210452A1 (es) | 2018-03-05 | 2019-03-04 | Inhibidores de la arginasa |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12054500B2 (es) |
| EP (1) | EP3761992A4 (es) |
| JP (1) | JP7402167B2 (es) |
| KR (1) | KR102656571B1 (es) |
| CN (1) | CN111818928A (es) |
| AU (1) | AU2019229978B2 (es) |
| BR (1) | BR112020017604A2 (es) |
| CA (1) | CA3091805A1 (es) |
| CL (1) | CL2020002271A1 (es) |
| CO (1) | CO2020012060A2 (es) |
| CR (1) | CR20200445A (es) |
| EA (1) | EA202092086A1 (es) |
| IL (1) | IL276813B2 (es) |
| MX (1) | MX2020009290A (es) |
| PE (1) | PE20210452A1 (es) |
| PH (1) | PH12020551352A1 (es) |
| SG (1) | SG11202008113RA (es) |
| UA (1) | UA127897C2 (es) |
| WO (1) | WO2019173188A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11530240B2 (en) * | 2017-06-09 | 2022-12-20 | The Regents Of The University Of California | Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering |
| EP3810615A4 (en) * | 2018-06-20 | 2022-03-30 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| KR20230026312A (ko) | 2020-06-17 | 2023-02-24 | 아르커스 바이오사이언시즈 인코포레이티드 | Cd73 억제제의 결정형 및 이의 용도 |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| TW202409083A (zh) | 2022-05-02 | 2024-03-01 | 美商阿克思生物科學有限公司 | 抗-tigit抗體及其用途 |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024059142A1 (en) | 2022-09-14 | 2024-03-21 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| TW202428286A (zh) | 2022-10-20 | 2024-07-16 | 美商阿克思生物科學有限公司 | Ｃｄ７３化合物之凍乾配方 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999019295A1 (en) | 1997-10-10 | 1999-04-22 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| CA2691373A1 (en) | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
| KR101690571B1 (ko) | 2008-06-17 | 2016-12-28 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 보로네이트 에스테르 화합물 및 이의 제약학적 조성물 |
| WO2010062927A2 (en) | 2008-11-26 | 2010-06-03 | Abbott Laboratories | Novel substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers |
| WO2010075863A1 (en) | 2008-12-29 | 2010-07-08 | University Of Tartu (Tartu Ülikool) | Arginase inhibitors for the treatment of depression |
| RS58965B1 (sr) | 2009-01-26 | 2019-08-30 | Univ Pennsylvania | Inhibitori arginaze i postupci upotrebe |
| MX348422B (es) | 2010-04-22 | 2017-06-12 | Mars Inc | Inhibidores de arginasa y sus aplicaciones terapeuticas. |
| SI2632927T1 (sl) * | 2010-10-26 | 2016-08-31 | Mars, Incorporated | Boronati kot inhibitorji arginaze |
| US8894970B2 (en) | 2010-12-31 | 2014-11-25 | Corridor Pharmaceuticals, Inc. | Arginase inhibitors and methods of use thereof |
| JP5993459B2 (ja) | 2011-10-19 | 2016-09-14 | マーズ インコーポレイテッド | アルギナーゼ阻害剤およびそれらの治療用途 |
| IN2014DN09678A (es) | 2012-04-18 | 2015-07-31 | Mars Inc | |
| WO2014007831A1 (en) | 2012-07-06 | 2014-01-09 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| CA2915054A1 (en) | 2013-06-12 | 2014-12-18 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CN106535635A (zh) | 2014-04-15 | 2017-03-22 | 美国陶氏益农公司 | 作为杀真菌剂的金属酶抑制剂化合物 |
| CL2014002403A1 (es) | 2014-09-11 | 2015-01-09 | Univ Pontificia Catolica Chile | Metodo para la preparacion enantioselectiva y purificacion del acido 2(s)-amino-6-boronohexanoico (abh) a partir de la disolucion de bpb-ni-gly en tetrahidrofurano, neutralizacion y posterior extraccion con diclorometano, disolucion en un alcohol c1-c5, enfriamiento para lograr la precipitacion de bpb, obtencion de abh y su posterior purificacion. |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| WO2016100555A1 (en) | 2014-12-18 | 2016-06-23 | Inception 4, Inc. | Boronic acid derivatives and uses thereof |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3313410A4 (en) * | 2015-06-23 | 2019-01-02 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| LT3368541T (lt) | 2015-10-30 | 2020-09-25 | Calithera Biosciences, Inc. | Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| US11291674B2 (en) | 2016-11-08 | 2022-04-05 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| PE20210046A1 (es) | 2018-03-05 | 2021-01-08 | Bristol Myers Squibb Co | Agonistas de fenilpirrolidinona del receptor 2 de formil peptido |
| EP3810615A4 (en) | 2018-06-20 | 2022-03-30 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
-
2019
- 2019-03-04 IL IL276813A patent/IL276813B2/en unknown
- 2019-03-04 UA UAA202006325A patent/UA127897C2/uk unknown
- 2019-03-04 EP EP19764594.8A patent/EP3761992A4/en active Pending
- 2019-03-04 SG SG11202008113RA patent/SG11202008113RA/en unknown
- 2019-03-04 CN CN201980017421.6A patent/CN111818928A/zh active Pending
- 2019-03-04 KR KR1020207028200A patent/KR102656571B1/ko active IP Right Grant
- 2019-03-04 US US16/978,335 patent/US12054500B2/en active Active
- 2019-03-04 WO PCT/US2019/020507 patent/WO2019173188A1/en active Application Filing
- 2019-03-04 CR CR20200445A patent/CR20200445A/es unknown
- 2019-03-04 EA EA202092086A patent/EA202092086A1/ru unknown
- 2019-03-04 PE PE2020001352A patent/PE20210452A1/es unknown
- 2019-03-04 JP JP2020546139A patent/JP7402167B2/ja active Active
- 2019-03-04 CA CA3091805A patent/CA3091805A1/en active Pending
- 2019-03-04 MX MX2020009290A patent/MX2020009290A/es unknown
- 2019-03-04 BR BR112020017604-4A patent/BR112020017604A2/pt unknown
- 2019-03-04 AU AU2019229978A patent/AU2019229978B2/en active Active
-
2020
- 2020-08-28 PH PH12020551352A patent/PH12020551352A1/en unknown
- 2020-09-02 CL CL2020002271A patent/CL2020002271A1/es unknown
- 2020-09-29 CO CONC2020/0012060A patent/CO2020012060A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102656571B1 (ko) | 2024-04-11 |
| CA3091805A1 (en) | 2019-09-12 |
| CO2020012060A2 (es) | 2021-01-18 |
| PH12020551352A1 (en) | 2021-06-21 |
| IL276813B1 (en) | 2024-05-01 |
| WO2019173188A1 (en) | 2019-09-12 |
| CL2020002271A1 (es) | 2021-04-09 |
| EA202092086A1 (ru) | 2021-02-09 |
| CR20200445A (es) | 2021-04-27 |
| IL276813B2 (en) | 2024-09-01 |
| SG11202008113RA (en) | 2020-09-29 |
| IL276813A (en) | 2020-10-29 |
| KR20200128117A (ko) | 2020-11-11 |
| JP2021516237A (ja) | 2021-07-01 |
| CN111818928A (zh) | 2020-10-23 |
| US20210002306A1 (en) | 2021-01-07 |
| UA127897C2 (uk) | 2024-02-07 |
| MX2020009290A (es) | 2020-09-28 |
| AU2019229978B2 (en) | 2024-05-30 |
| AU2019229978A1 (en) | 2020-10-15 |
| JP7402167B2 (ja) | 2023-12-20 |
| EP3761992A1 (en) | 2021-01-13 |
| US12054500B2 (en) | 2024-08-06 |
| EP3761992A4 (en) | 2021-11-24 |
| BR112020017604A2 (pt) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210452A1 (es) | Inhibidores de la arginasa | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| PH12021500014A1 (en) | Fused ring compounds | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| PH12021551065A1 (en) | Fused ring compounds | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2017001124A1 (es) | Agentes inmunomoduladores | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| PH12018502329A1 (en) | Modulators of the integrated stress pathway | |
| AU2017261336A1 (en) | Modulators of the integrated stress pathway | |
| DOP2022000194A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| AU2017260374A1 (en) | Modulators of the integrated stress pathway | |
| EA201691978A1 (ru) | Соединения в качестве модуляторов ror гамма | |
| CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
| BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
| CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
| AR112448A1 (es) | Derivados de xantina sustituidos | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
| EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 | |
| UY37316A (es) | Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |